RxDoctor Payments Data

Asma Malik, MD

Neurology · Columbia, MONPI 1144612219

Payments from drug & device makers

$2,777in general payments, 2019–2025

Across 55 payments — averaging $50.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Medtronic$979
  • AbbVie$146
  • Sanofi-aventis U.S. LLC$103
  • SK Life Science, Inc.$84
  • Amneal Pharmaceuticals LLC$71
  • plus $314 from 11 others

What the payments were for

  • Travel & lodging$1,15542%
  • Food & beverage$1,62358%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,777 in reported general payments places this provider in the 55th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$43,714
Medicare patients
228
Services billed
651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyclarysOmaveloxolone13$406,626
IngrezzaValbenazine Tosylate16$133,345
RytaryCarbidopa/Levodopa75$91,633
AustedoDeutetrabenazine17$82,510
NuplazidPimavanserin Tartrate13$64,870
Emgality PenGalcanezumab-Gnlm62$51,633
Carbidopa-LevodopaCarbidopa/Levodopa549$23,140
UbrelvyUbrogepant12$13,472
Aimovig AutoinjectorErenumab-Aooe15$12,552
NeuproRotigotine11$8,289
Rasagiline Mesylate46$6,641
AmantadineAmantadine Hcl83$6,243
Lacosamide32$4,978
Droxidopa12$4,794
Carbidopa28$4,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$29$133,34516 claims
Amneal Pharmaceuticals LLCRytary$71$91,63375 claims
Teva Pharmaceuticals USA, Inc.Austedo$68$82,51017 claims
AbbVieUbrelvy$146$13,47212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 381 neurology providers in Missouri.

Other neurology in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →